NonNarcotic Pain Control in Percutaneous Needle Tenotomy of Elbow

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-12

Study Completion Date

2025-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a double-blind, randomized controlled trial comparing the effectiveness of oral acetaminophen, diclofenac, and tramadol in reducing the consumption of narcotic doses (primary outcome) and minimizing patients' exposure to narcotics (secondary outcome) following an ultrasound-guided percutaneous needle tenotomy procedure on the lateral elbow.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis

NCT00833794

Pain Osteoarthritis

COMPLETED PHASE3

Non-Narcotic Pain Control After ACL Reconstruction

NCT06973785

ACL - Anterior Cruciate Ligament Rupture ACL Injuries

RECRUITING PHASE3

A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb

NCT00743587

Osteoarthritis Thumbs

COMPLETED PHASE1

Intravenous Acetaminophen for Non-Narcotic Postoperative Pain Management Following Knee Arthroscopy

NCT02025634

Pain, Postoperative

COMPLETED PHASE4

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

NCT01789216

Orthopaedic Fractures

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tramadol is currently the standard post-procedure medication. Acetaminophen will be prescribed (1000 mg) and should be taken every 8 hours if pain is present. Tylenol should be the first taken for pain. If pain persist, the study kit containing the blinded, pain-controlled capsules will be taken second. Both diclofenac potassium (50mg) and tramadol (50mg) will be provided in identical-looking capsules and randomly assigned to patients in sealed packets by a physician, ensuring the double-blind nature of the study and be instructed to use every 8 hours as needed for pain If pain is still not adequately controlled an hour after taking the blinded study pack, a rescue medication, consisting of tramadol 50mg capsules, will also be supplied to the NSAID group in sealed packets while rescue medication of oral diclofenac will be provided to the opioid group. These medications will be administered immediately after the tenotomy procedure to all participants. The primary endpoint of the study will be the total count of tramadol doses taken by each group at the 10 day (± 4 days) postoperative follow-up. Pill counts from sealed packages and the use of rescue narcotics will be verified during the in-person visit at 10 days (± 4 days) .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elbow Pain Chronic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study is a double-blind, randomized controlled trial comparing the effectiveness of oral acetaminophen, diclofenac, and tramadol in reducing the consumption of narcotic doses (primary outcome) and minimizing patients' exposure to narcotics (secondary outcome) following an ultrasound-guided percutaneous needle tenotomy procedure on the lateral elbow.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diclofenac

50mg

Group Type ACTIVE_COMPARATOR

Diclofenac

Intervention Type DRUG

50mg every 8hours as needed for pain

Acetaminophen

Intervention Type OTHER

1000mg every 8hours as needed for pain

Tramadol

50mg

Group Type ACTIVE_COMPARATOR

Tramadol

Intervention Type DRUG

50mg every 8hours as needed for pain

Acetaminophen

Intervention Type OTHER

1000mg every 8hours as needed for pain

Acetaminophen

1000mg

Group Type SHAM_COMPARATOR

Acetaminophen

Intervention Type OTHER

1000mg every 8hours as needed for pain

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diclofenac

50mg every 8hours as needed for pain

Intervention Type DRUG

Tramadol

50mg every 8hours as needed for pain

Intervention Type DRUG

Acetaminophen

1000mg every 8hours as needed for pain

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged 18-65 years
* Percutaneous Needle Tenotomy of Lateral Elbow Procedure
* Ability to take oral medication and willingness to participate in a 2-week follow-up pill counts
* Musculoskeletal ultrasound or MRI with diagnosis of tendinosis of the common extensor tendon of the elbow

Exclusion Criteria

* • Any full thickness common extensor tendon tear of the elbow

* Prior history of elbow surgery
* Symptomatic cervical radiculopathy
* Concurrent symptoms of the medial elbow
* Treatment with another investigational drug or other intervention concurrently or previously that would interfere with postoperative pain control
* Psychiatric illness that impedes evaluation of pain and/or narcotics use
* No history of inflammatory arthritis, diabetes, chronic regional pain syndrome, connective tissue disease, fibromyalgia or autoimmune disease
* No contraindications to NSAIDs or Opioids

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No